secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0000879169-24-000042
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte reports FY23 revenue $3.7B (+14%), Jakafi $2.59B, Opzelura $338M; guides 2024
--------------------------------------------------------------------------------

- Total FY23 net product and royalty revenue $3.7B (+14% Y/Y); Q4 total revenue topped $1B for first time.
- Jakafi FY23 net product revenue $2.59B (+8%); 2024 Jakafi guidance $2.69-$2.75B.
- Opzelura FY23 net product revenue $338M (+162%) driven by atopic dermatitis and vitiligo launch.
- GAAP FY23 net income $598M (diluted EPS $2.65); Non-GAAP net income $795M (diluted EPS $3.52).
- Acquired worldwide rights to tafasitamab (Monjuvi/Minjuvi) from MorphoSys for $25M upfront.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916924000042/0000879169-24-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916924000042/incy-20240213.htm
  HTML page:      https://secwatch.observer/filing/0000879169-24-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer